[{"address1": "15 Crosby Drive", "city": "Bedford", "state": "MA", "zip": "01730", "country": "United States", "phone": "781 357 4000", "fax": "781 275 7562", "website": "https://www.ocutx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.", "fullTimeEmployees": 267, "companyOfficers": [{"maxAge": 1, "name": "Mr. Donald  Notman Jr.", "title": "CFO, COO & Principal Accounting Officer", "fiscalYear": 2023, "totalPay": 679770, "exercisedValue": 0, "unexercisedValue": 90888}, {"maxAge": 1, "name": "Dr. Jeffrey S. Heier M.D.", "age": 63, "title": "Chief Scientific Officer", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 86162, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Pravin U. Dugel M.D.", "age": 60, "title": "Executive Chairman, President & CEO", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter K. Jarrett Ph.D.", "age": 67, "title": "Chief Technology Officer", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. William S. Slattery Jr.", "title": "Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Todd D.C. Anderman J.D.", "title": "Chief Legal Officer & Corporate Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. William H. Ransone II", "title": "Vice President of Global Sales & Marketing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Barry  Rubenstein M.S.", "title": "Chief Human Resources Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Steve  Meyers", "title": "Chief Commercial Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter K. Kaiser M.D.", "title": "Chief Development Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 7, "overallRisk": 7, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 7.48, "open": 7.48, "dayLow": 7.18, "dayHigh": 7.68, "regularMarketPreviousClose": 7.48, "regularMarketOpen": 7.48, "regularMarketDayLow": 7.18, "regularMarketDayHigh": 7.68, "beta": 1.218, "forwardPE": -7.109375, "volume": 1229707, "regularMarketVolume": 1229707, "averageVolume": 909681, "averageVolume10days": 995680, "averageDailyVolume10Day": 995680, "bid": 5.52, "ask": 9.28, "bidSize": 200, "askSize": 200, "marketCap": 1144539776, "fiftyTwoWeekLow": 4.06, "fiftyTwoWeekHigh": 11.775, "priceToSalesTrailing12Months": 18.627972, "fiftyDayAverage": 8.3989, "twoHundredDayAverage": 8.16165, "currency": "USD", "enterpriseValue": 792446848, "profitMargins": -2.8374398, "floatShares": 122440932, "sharesOutstanding": 157216992, "sharesShort": 10872561, "sharesShortPriorMonth": 10736923, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0692, "heldPercentInsiders": 0.01148, "heldPercentInstitutions": 0.86522, "shortRatio": 11.85, "shortPercentOfFloat": 0.0694, "impliedSharesOutstanding": 157216992, "bookValue": 2.247, "priceToBook": 3.2398756, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -174338000, "trailingEps": -1.29, "forwardEps": -1.02, "enterpriseToRevenue": 12.897, "enterpriseToEbitda": -5.698, "52WeekChange": -0.005319178, "SandP52WeekChange": 0.22903383, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "OCUL", "underlyingSymbol": "OCUL", "shortName": "Ocular Therapeutix, Inc.", "longName": "Ocular Therapeutix, Inc.", "firstTradeDateEpochUtc": 1406295000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "b2e86f5b-6ae3-30af-bdc2-4b9ad5a2cf9e", "messageBoardId": "finmb_41955650", "gmtOffSetMilliseconds": -18000000, "currentPrice": 7.28, "targetHighPrice": 22.0, "targetLowPrice": 14.0, "targetMeanPrice": 18.22222, "targetMedianPrice": 18.0, "recommendationMean": 1.44444, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 9, "totalCash": 427220000, "totalCashPerShare": 2.717, "ebitda": -139063008, "totalDebt": 75124000, "quickRatio": 12.593, "currentRatio": 13.009, "totalRevenue": 61442000, "debtToEquity": 21.341, "revenuePerShare": 0.447, "returnOnAssets": -0.27356002, "returnOnEquity": -0.96888, "grossProfits": -47181000, "freeCashflow": -79564752, "operatingCashflow": -117702000, "revenueGrowth": 0.023, "grossMargins": -0.76789004, "ebitdaMargins": -2.26332, "operatingMargins": -2.9820402, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]